Cargando…

The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2

Xanthine oxidoreductase (XOR) is a rate-limiting enzyme in purine catabolism that acts as a novel regulator of adipogenesis. In pathological states, xanthine oxidoreductase activity increases to produce excess reactive oxygen species (ROS). The nuclear factor erythroid 2-related factor 2 (Nrf2) is a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Higa, Yoshiki, Hiasa, Masahiro, Tenshin, Hirofumi, Nakaue, Emiko, Tanaka, Mariko, Kim, Sooha, Nakagawa, Motosumi, Shimizu, So, Tanimoto, Kotaro, Teramachi, Jumpei, Harada, Takeshi, Oda, Asuka, Oura, Masahiro, Sogabe, Kimiko, Hara, Tomoyo, Sumitani, Ryohei, Maruhashi, Tomoko, Yamagami, Hiroki, Endo, Itsuro, Matsumoto, Toshio, Tanaka, Eiji, Abe, Masahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854541/ https://www.ncbi.nlm.nih.gov/pubmed/36670994 http://dx.doi.org/10.3390/antiox12010133

Ejemplares similares

Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors
por: Nakaue, Emiko, et al.
Publicado: (2023)

Mechanical unloading aggravates bone destruction and tumor expansion in myeloma
por: Tanimoto, Kotaro, et al.
Publicado: (2021)

The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat
por: Ashtar, Mohannad, et al.
Publicado: (2020)

TGF‐β‐activated kinase‐1 inhibitor LL‐Z1640‐2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF‐α and RANKL expression
por: Tenshin, Hirofumi, et al.
Publicado: (2022)

Reveromycin A, a novel acid-seeking agent, ameliorates bone destruction and tumor growth in multiple myeloma
por: Watanabe, Keiichiro, et al.
Publicado: (2021)

Therapeutic efficacy of the resorcylic acid lactone LL‐Z1640‐2 for adult T‐cell leukaemia/lymphoma
por: Oura, Masahiro, et al.
Publicado: (2023)

TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma
por: Teramachi, Jumpei, et al.
Publicado: (2020)

Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase
por: Harada, Takeshi, et al.
Publicado: (2022)

Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors
por: Bat-Erdene, Ariunzaya, et al.
Publicado: (2016)

The importance of retaining physical functions to prevent skeletal‐related events in multiple myeloma patients with bone disease
por: Miki, Hirokazu, et al.
Publicado: (2022)

PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ
por: Iwasa, Masami, et al.
Publicado: (2019)

Myeloma–Bone Interaction: A Vicious Cycle via TAK1–PIM2 Signaling
por: Harada, Takeshi, et al.
Publicado: (2021)

Acute Myeloid Leukemia Developing with Acute Pancreatitis Mimicking Autoimmune Pancreatitis
por: Sumitani, Ryohei, et al.
Publicado: (2021)

Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat
por: Jordan, Andreas, et al.
Publicado: (2018)

Effective impairment of myeloma cells and their progenitors by hyperthermia
por: Miki, Hirokazu, et al.
Publicado: (2017)

Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents
por: Teramachi, Jumpei, et al.
Publicado: (2023)

Xanthine Oxidase Inhibition by Febuxostat Attenuates Experimental Atherosclerosis in Mice
por: Nomura, Johji, et al.
Publicado: (2014)

The potential renoprotection of xanthine oxidase inhibitors: Febuxostat versus allopurinol
por: Ryu, Dong-Ryeol
Publicado: (2017)

Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia
por: Omizo, Hiroki, et al.
Publicado: (2020)

Febuxostat, a Xanthine Oxidase Inhibitor, Decreased Macrophage Matrix Metalloproteinase Expression in Hypoxia
por: Wei, Shuoyu, et al.
Publicado: (2020)

Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice
por: Mizuno, Yu, et al.
Publicado: (2019)

Different inhibitory potency of febuxostat towards mammalian and bacterial xanthine oxidoreductases: insight from molecular dynamics
por: Kikuchi, Hiroto, et al.
Publicado: (2012)

Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats
por: Shirakura, Takashi, et al.
Publicado: (2016)

Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice
por: Yisireyili, Maimaiti, et al.
Publicado: (2017)

Osteoblast/osteocyte-derived interleukin-11 regulates osteogenesis and systemic adipogenesis
por: Dong, Bingzi, et al.
Publicado: (2022)

A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration
por: Amachi, Ryota, et al.
Publicado: (2016)

Pathogenesis and treatment of multiple myeloma bone disease
por: Hiasa, Masahiro, et al.
Publicado: (2021)

Long-Term Inhibition of Xanthine Oxidase by Febuxostat Does Not Decrease Blood Pressure in Deoxycorticosterone Acetate (DOCA)-Salt Hypertensive Rats
por: Szasz, Theodora, et al.
Publicado: (2013)

Integrated in silico – in vitro strategy for the discovery of potential xanthine oxidase inhibitors from Egyptian propolis and their synergistic effect with allopurinol and febuxostat
por: Ghallab, Dina S., et al.
Publicado: (2022)

Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation
por: Hanson, Derek James, et al.
Publicado: (2015)

Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study
por: Oyama, Jun-ichi, et al.
Publicado: (2016)

Febuxostat, an Inhibitor of Xanthine Oxidase, Suppresses Lipopolysaccharide-Induced MCP-1 Production via MAPK Phosphatase-1-Mediated Inactivation of JNK
por: Nomura, Johji, et al.
Publicado: (2013)

SAT641 The Xanthine Oxidoreductase Inhibitor, Febuxostat, Protects Against Nanomaterial Inhalation-induced Endocrine, Microvascular And Reproductive Dysfunction During Gestation
por: Bowdridge, Elizabeth, et al.
Publicado: (2023)

Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study
por: Maruhashi, Tatsuya, et al.
Publicado: (2022)

Establishment of a new rehabilitation program using masticatory training food for jaw deformity patients
por: Watanabe, Masahiko, et al.
Publicado: (2022)

Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein
por: Ikemura, Kenji, et al.
Publicado: (2019)

Febuxostat, a Xanthine Oxidoreductase Inhibitor, Decreases NLRP3-dependent Inflammation in Macrophages by Activating the Purine Salvage Pathway and Restoring Cellular Bioenergetics
por: Nomura, Johji, et al.
Publicado: (2019)

Febuxostat methanol solvate
por: Jiang, Qi-Ying, et al.
Publicado: (2011)

Febuxostat ethanol monosolvate
por: Gelbrich, Thomas, et al.
Publicado: (2020)

Successful febuxostat desensitization in a patient with febuxostat hypersensitivity: A Malaysian experience
por: Sulaiman, Narisa, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dsfdemum06f939t6kn4bg84v3l